appScorecard
Performance
LowHasn't faired well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Glenmark Life Sciences Ltd
GLS
Price Chart
Scorecard
Performance
LowHasn't faired well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Glenmark Life Sciences Ltd is a manufacturer of pharmaceutical preparation. The Company was founded in June 2011 and is located in Solapur, India.
Investor PresentationView older
View Older PresentationsPeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Nirma, 3 private equity firms in race to buy Glenmark Life Sciences
1 week ago•Business Standard
Glenmark Life Hits New 52-Wk High on Strong Q4, PAT Jumps 48%
1 month ago•Investing.com
Glenmark Life hits 52-week high as strong Q4 earnings bolsters sentiment
1 month ago•Moneycontrol
Recent EventsAll events
Disclosure under SEBI Takeover Regulations
Glenmark Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. | Download
Glenmark Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. | Download
Cash Dividend
Interim • Div/Share: ₹ 21
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant